Neurology
In vitro and rat studies identified a mAb against the ADCYAP1-derived peptides PACAP-38 and PACAP-27 that could help treat migraine. In vitro screening of B cell cultures of PACAP-38-immunized rabbits for mAbs that inhibit both PACAP-38 and PACAP-27, followed by humanization of the top hit, yielded ALD1910, which bound PACAP-38 and PACAP-27 with Kd values of 22 and 59 pM, respectively. In a rat model of migraine, the mAb decreased facial temperature and lacrimation, both markers of migraine pain, compared with vehicle, and had a serum half-life of 188 hours. Next steps by Alder BioPharmaceuticals Inc. could include testing ALD1910 in other models of migraine...
BCIQ Company Profiles
BCIQ Target Profiles
Adenylate cyclase activating polypeptide pituitary (ADCYAP1) (PACAP)